← Policy & Regulation: Pricing and Tariff Control (all topics)
NPPA price caps - medical devices
What it is
Medical devices are notified as drugs, so NPPA can cap them under the DPCO, 2013 - either by scheduling a device or, more commonly, under Para 19 in public interest
A second lever is trade margin rationalisation, which caps the margin between price to distributor and MRP rather than the price itself, targeting distribution mark-ups rather than manufacturing cost
Impact on industries
- Large one-off gains in patient affordability - coronary stent and knee implant caps cut prices roughly 65-85%, and expanded volumes partly offset lower unit realisation
- Compresses the distribution layer hardest, since most of the capped mark-up sat with distributors and hospitals rather than the manufacturer
- Unpredictable by design - Para 19 can be invoked on any device at any time, so pricing power on any high-margin category is contingent rather than durable
- Discourages premium and imported variants: some global suppliers withdrew higher-end stent and implant models after capping, narrowing clinical choice